OneMedNet
ONMD on Nasdaq. OneMedNet sells clinical imaging data and patient records to life science partners. Market value $303m.
Price checks use the past 12 months to June 2026. Some use the latest annual report instead, as marked. Quality checks use five annual reports, the latest for the year to December 2025.
Should I look at this?
Look carefully before going further
Why it could be worth it
Read the warning sign in its own filings
This is not advice. Check the numbers below.
For every $100 of what the whole company costs, it produced $-2.48 of spare cash last year. A savings account pays about $4.
The filings do not give us enough to work this out.
The filings do not give us enough to work this out.
Quality score: 30 of 100. Price score: 0 of 100. Our list needs 70 on quality and 60 on price.
$5.11 a share, 4% above its 1-year low
Over the past year the price has ranged from $4.90 to $42.20.
Pays no dividend
Prices from Monday’s close (5 October).
Five years of cash, in billions
| Revenue | ||||
| Revenue | $1m | $1m | $643,000 | $1m |
| Operating margin | ||||
| Operating margin | -669.1% | -671.2% | -1493.8% | -711.3% |
| Debt to equity | ||||
| Debt to equity | n/a | n/a | n/a | n/a |
| Shares outstanding | ||||
| Shares outstanding | 0.03bn | 0.03bn | 0.05bn | 0.06bn |
Health checks
- Free cash flow positive0 of 4 years
- Accounting checksSkipped: company is not yet profitable
- DebtUnknown
- Revenue growth, five yearsSlow, 5.6% a year
- Buying back its own sharesNo, 84% more shares since 2022
The quarter to June 2026
How the business did, compared with the same quarter a year earlier.
- Sales: $292,000 last quarter, up 88% on a year ago.
- A loss of $2 million, after a profit of $3 million a year ago.
- It loses 696 cents on each $1 of sales, compared with 2048 cents a year earlier.
- 51% more shares than a year ago. Each share owns a bit less of the company.
- Sales grew on a year ago in 3 of the last 4 quarters.
| Quarter to | Amount |
|---|---|
| September 2024 | $142,000 |
| December 2024 | $26,000 |
| March 2025 | $137,000 |
| June 2025 | $155,000 |
| September 2025 | $177,000 |
| December 2025 | $891,000 |
| March 2026 | $96,000 |
| June 2026 | $292,000 |
| Quarter to | Amount |
|---|---|
| September 2024 | -$2m |
| December 2024 | -$2m |
| March 2025 | -$2m |
| June 2025 | $3m |
| September 2025 | -$741,000 |
| December 2025 | -$3m |
| March 2026 | -$2m |
| June 2026 | -$2m |
From the company's quarterly reports to the SEC.
Dates
- Next results (estimated)
- n/a
- Last annual report (10-K)
- 30 March 2026
- Next quarterly (estimated, 10-Q)
- 13 November 2026
Who owns it
None of the long-term investors we follow own it. 22 funds in all.
Largest holders overall
- Savant Capital$5mNew
- Vanguard Capital Management$819,221Added
- Geode Capital Management$237,709
- Vanguard Fiduciary Trust$97,909
- BlackRock$86,017Added
- State Street$82,974
- Discovery Capital Management$79,811
- PNC Financial Services Group$73,469Added
- OpenArc Corporate Advisory$69,261Added
- Northern Trust$33,300Cut
From 13F filings for the quarter ended 30 June 2026.
Big holders and activists
1 investor owns more than 5%.
- TD SECURITIES (USA) LLCPassive investorat least 6.2%−2.7 pts(filed with 3 related holders)Since 30 September 2025
- DISCOVERY CAPITAL MANAGEMENT, LLCPassive investorSold down below 5%Since 30 September 2025
- COWEN AND COMPANY, LLCPassive investorSold down below 5%Since 31 December 2024
| Holder | Stake | Since | |
|---|---|---|---|
TD SECURITIES (USA) LLC Passive investor | at least 6.2%−2.7 pts (filed with 3 related holders) | 30 September 2025 | |
DISCOVERY CAPITAL MANAGEMENT, LLC Passive investor | Sold down below 5% | 30 September 2025 | |
COWEN AND COMPANY, LLC Passive investor | Sold down below 5% | 31 December 2024 |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
In the last 12 months, 4 insiders bought $3m of shares on the open market. 1 sold $218,296.
- Yu JeffreyChief Medical Officer, DirectorBought
- Date
- 10 September 2026
- Shares
- 142,857
- Price
- $0.63
- Value
- $90,000
- Kosasa ThomasDirectorBought
- Date
- 30 July 2026
- Shares
- 1,449,275
- Price
- $0.69
- Value
- $1,000,000
- Green AaronChief Executive Officer, DirectorBought
- Date
- 23 June 2026
- Shares
- 36,650
- Price
- $0.57
- Value
- $20,891
- Yu JeffreyChief Medical Officer, DirectorBought
- Date
- 23 June 2026
- Shares
- 158,730
- Price
- $0.63
- Value
- $100,000
- Yu JeffreyChief Medical Officer, DirectorBought
- Date
- 16 June 2026
- Shares
- 172,414
- Price
- $0.58
- Value
- $100,000
- Green AaronChief Executive Officer, DirectorBought
- Date
- 15 June 2026
- Shares
- 18,702
- Price
- $0.54
- Value
- $10,099
- Green AaronChief Executive Officer, DirectorBought
- Date
- 12 June 2026
- Shares
- 36,920
- Price
- $0.56
- Value
- $20,675
- Kosasa ThomasDirectorBought
- Date
- 12 June 2026
- Shares
- 158,730
- Price
- $0.63
- Value
- $100,000
- Kosasa ThomasDirectorBought
- Date
- 18 May 2026
- Shares
- 268,817
- Price
- $0.93
- Value
- $250,000
- Kosasa ThomasDirectorBought
- Date
- 23 April 2026
- Shares
- 280,898
- Price
- $0.89
- Value
- $249,999
| Date | Who | Did | Shares | Price | Value |
|---|---|---|---|---|---|
| 10 September 2026 | Yu Jeffrey Chief Medical Officer, Director | Bought | 142,857 | $0.63 | $90,000 |
| 30 July 2026 | Kosasa Thomas Director | Bought | 1,449,275 | $0.69 | $1,000,000 |
| 23 June 2026 | Green Aaron Chief Executive Officer, Director | Bought | 36,650 | $0.57 | $20,891 |
| 23 June 2026 | Yu Jeffrey Chief Medical Officer, Director | Bought | 158,730 | $0.63 | $100,000 |
| 16 June 2026 | Yu Jeffrey Chief Medical Officer, Director | Bought | 172,414 | $0.58 | $100,000 |
| 15 June 2026 | Green Aaron Chief Executive Officer, Director | Bought | 18,702 | $0.54 | $10,099 |
| 12 June 2026 | Green Aaron Chief Executive Officer, Director | Bought | 36,920 | $0.56 | $20,675 |
| 12 June 2026 | Kosasa Thomas Director | Bought | 158,730 | $0.63 | $100,000 |
| 18 May 2026 | Kosasa Thomas Director | Bought | 268,817 | $0.93 | $250,000 |
| 23 April 2026 | Kosasa Thomas Director | Bought | 280,898 | $0.89 | $249,999 |
From Form 4 filings: insiders must report trades in their own company's shares within two days.
Warning signs in its filings
Problems the company itself reported to the SEC, in its own words.
3 serious warning signs in OneMedNet’s filings.
We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.
We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 30 Mar 2026, plus the 10-Q filed 14 Aug 2026 and 5 later 8-Ks.
Doubt it can keep going
SeriousThe company or its auditor warned it may not have enough money to last the next year.
“Therefore, these conditions raise substantial doubt about the Company’s ability to continue as a going concern.”
Show the full paragraph
The Company has incurred recurring operating losses since its inception, including $ 2.3 million and $ 2.1 million for the three months ended June 30, 2026 and 2025, respectively. In addition, the Company had an accumulated deficit of $ 109.0 million as of June 30, 2026. The Company’s cash balance of $ 0.4 million is not adequate to fund its operations through at least twelve months from the date these condensed consolidated financial statements were available for issuance. Therefore, these conditions raise substantial doubt about the Company’s ability to continue as a going concern.
From the 10-Q filed 14 August 2026, Part I, Item 1. Financial Statements. Read it in the filing
Weak checks on its own accounts
SeriousThe company said its checks on its own accounts did not work at the end of its latest quarter. Mistakes could slip into the numbers.
“Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that as of June 30, 2026, our disclosure controls and procedures were ineffective because of material weaknesses in our internal controls over financial reporting which were not designed properly to ensure proper identification of non-routine transactions and ensure appropriate segregation of duties.”
Show the full paragraph
Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act), as of June 30, 2026. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that as of June 30, 2026, our disclosure controls and procedures were ineffective because of material weaknesses in our internal controls over financial reporting which were not designed properly to ensure proper identification of non-routine transactions and ensure appropriate segregation of duties.
From the 10-Q filed 14 August 2026, Part I, Item 4. Controls and Procedures. Read it in the filing
Its past accounts can't be relied on
SeriousIt told the SEC its earlier accounts should no longer be relied on, usually because they contained errors.
8-K Item 4.02 filed 5 Nov 2024: the company said its earlier financial statements should no longer be relied on.
From an 8-K filed 5 November 2024: Previously issued accounts should no longer be relied on. Open the filing
A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.
What could go wrong
- It owes more than it owns on paper (negative equity). Often that's from borrowing to buy back shares.
Whether the price already reflects the risks is what the deep dive is for.
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.